A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients

A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients

Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posacon...

Full description

Saved in:
Bibliographic Details
Main Authors: Bettina Gerner (Author), Fatemeh Aghai-Trommeschlaeger (Author), Sabrina Kraus (Author), Götz Ulrich Grigoleit (Author), Sebastian Zimmermann (Author), Max Kurlbaum (Author), Hartwig Klinker (Author), Nora Isberner (Author), Oliver Scherf-Clavel (Author)
Format: Book
Published: MDPI AG, 2022-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items